st-400
Generic: Autologous CD34-positive BCL11A-disrupted Hematopoietic Progenitor Cells ST-400·Code: ST-400
st-400: 1 clinical trial tracked.
st-400 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about st-400, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trials (1)
An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant
Primary endpoint: Adverse Events
Observational8 targetStarted 2021-12Completion 2038-077 sites · United StatesSangamo Therapeutics